Temporary disruptions in routine and nonemergency medical care access and delivery have been observed during periods of considerable community transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). However, medical care delay or avoidance might increase morbidity and mortality risk associated with treatable and preventable health conditions and might contribute to reported excess deaths directly or indirectly related to COVID-19.
News and Updates for Healthcare Professionals
Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020
The FDA’s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health
The U.S. Food and Drug Administration’s mission is to protect and promote the public health, both in the U.S. and globally, by ensuring the safety and effectiveness of the products we regulate. Nowhere is this public health mission more evident than in the FDA’s role in the scientific and regulatory oversight of vaccines. One of the agency’s highest priorities is ensuring the quality, safety and effectiveness of vaccines. This deep and abiding commitment is something that we consider essential to engendering the public’s trust in vaccines.
AHRQ Evidence-Based Practice Update
Strategies for Patient, Family, and Caregiver Engagement
NIH establishes Centers for Research in Emerging Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging Infectious Diseases (CREID).
Consensus Statement Outlines Recommendations for Diabetes Self-Management Education and Support
A consensus statement published in Diabetes Care outlines the benefits and barriers associated with diabetes self-management education and support (DSMES) in adults with type 2 diabetes.
Are You Aware: Quick Facts About Kidney Disease
In the United States, it is estimated that about 37 million adults have chronic kidney disease (CKD).1 Generally, sleep problems have been associated with higher mortality risk, chronic diseases such as heart disease, and progression of CKD.2-4 As a considerable proportion of the US population has reported sleep problems, prevalence is generally higher in adults with CKD than adults without CKD.3
In the 2013-2014 National Health and Nutrition Examination Survey, two in five (41.0%) adults with CKD stages 3 and 4 reported trouble sleeping compared with 29.2% in adults with CKD stages 1 and 2* and 27.1% in adults with no CKD. The percentage reporting sleep disorders was also higher in adults with CKD stages 3 and 4 (17.7%) and CKD stages 1 and 2 (13.6%) than in adults without CKD (9.6%). Nocturia (waking up during the night to urinate) was also more prevalent in adults with CKD—39.4% in CKD stages 3 and 4 and 38.7% in CKD stages 1 and 2—compared with 24.3% in adults with no CKD. On the other hand, inadequate sleep was similar among adults with and without CKD.
The higher burden of sleep problems among adults with CKD, especially with stages 3 and 4, highlights the importance for early detection and management of these symptoms in the primary and specialty care settings.
First-ever research network tackles diabetic foot complications
Foot ulcers are the leading cause of lower limb amputations in the United States.
EGT posts 600th Guideline Brief and Scorecard!
EGT has reached yet another milestone and has published its 600th Guideline Brief and Scorecard. This represents guidelines from 77 developer organizations and covers more than 52 clinical topics.
Even a Few Days of Steroids May Be Risky
Individually tailored falls prevention plan found no better than usual care for reducing serious injury
Large PCORI-, NIH-funded trial examined multipronged intervention in real-world settings.